Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Test to Detect T-Cell Immune Response to SARS-CoV-2 Using AI-Powered Platform Delivers Results in Real-Time

By LabMedica International staff writers
Posted on 27 Oct 2021

A new test to detect T-cell immune response to SARS-CoV-2 leverages the power of an AI-powered platform that enables genetic testing in any setting, at any time, with results available in real-time. More...

Hyris Ltd. (London, UK) has developed the rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with the Duke-NUS Medical School (Singapore). This new solution leverages the power of the renowned HYRIS bCUBE and the whole Hyris System. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

The Hyris System, Hyris' proprietary genetic testing platform, is an ideal Point of Care solution in the fight against COVID-19. Thanks to the power of the extremely portable proprietary hardware HYRIS bCUBE, the Hyris System works anywhere and at any time, successfully detecting the presence of coronavirus on surfaces and environments (the SARS-CoV-2 Environmental test) and COVID-19 infection in individuals (SARS-CoV-2 Human test), including all the main variants of concern that have emerged since July 2020.

The T-Cell clinical test kit developed through an exclusive licensing agreement between Hyris and Duke-NUS Medical School allows rapid and large-scale expansion of studies to track T-cell activity across the world while not requiring specialized or expensive equipment. The simple and rapid method to measure T-cell immune response to the SARS-CoV-2 virus helps to define the correlates of protection from T Cells and antibodies for the development of COVID-19 vaccines. Such a test is a prime example of how scientific innovation is the key to the fight against the SARS-CoV-2 virus in order to boost population immunity.

"Alongside with limiting the spread of SARS-CoV-2 new variants and potential hotspots, getting high immunity rates among populations is number one priority for policymakers and health institutions," said Stefano Lo Priore, Founder and CEO at Hyris. "Hyris integrated its solutions with a simple yet effective test, to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19."

Related Links:
Hyris Ltd. 
Duke-NUS Medical School


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.